Catalyst Pharmaceutical Partners Provides Update on FIRDAPSE(TM) Progress

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today provided an update on its progress with its lead investigational product, FIRDAPSETM. "Over the past six months, we have made great